Home / Health / Kids' Weight Drugs Spark Fierce Debate
Kids' Weight Drugs Spark Fierce Debate
16 Nov
Summary
- Weight-loss drugs show effectiveness in children as young as six.
- Nearly 40 percent of severely obese children in a trial achieved non-obese status.
- Doctors are divided on the long-term implications for children's growth.

New clinical trial data presented recently indicates that weight-loss medications can be effective for children as young as six years old. A study involving semaglutide, the active compound in Ozempic and Wegovy, found that almost 40 percent of participants with severe obesity achieved a non-obese status after 68 weeks. This marks a significant development as the drug's manufacturer plans to seek FDA approval for this younger age group, an expansion from its current authorization for those 12 and older.
While the effectiveness of these GLP-1 drugs in managing childhood obesity is evident, a significant division has emerged among medical professionals. Concerns are being raised about the potential long-term effects of appetite-suppressing drugs on children who are still developing. The World Health Organization has previously cautioned against their use in younger children due to a lack of data on developmental impacts.